FDA Clears Ocugen’s Phase II/III Trial for Stargardt Disease Gene Therapy
Ocugen’s OCU410ST gene therapy gets another green light. Next stop: a Phase II/III trial. The U.S. Food and Drug Administration…
FDA Grants Breakthrough Therapy Designation to Belite Bio’s Tinlarebant for Stargardt Disease
A once-daily oral pill for Stargardt? Tinlarebant takes a big step with FDA breakthrough status. In a major step forward…
latest posts
